Analysguiden has completed an analysis of Stayble Therapeutics and initiates equity research coverage

Analysguiden has completed an analysis of Stayble Therapeutics. The analysis is available at the following link: https://www.aktiespararna.se/analysguiden/nyheter/initieringsanalys-stayble-therapeutics-unik-behandling-diskrelaterad-ryggsmarta

“We are focusing on continuing the development of STA363 to offer an effective and alternative treatment for chronic back pain. While we continue to work on our phase 2b study, we also want to take the opportunity to increase the knowledge and understanding of our ambitions regarding the treatment of back pain and talk more about our drug candidate. As a part of this, we have established a partnership with Analysguiden to give investors a better understanding of Stayble Therapeutics,” comments CEO Andreas Gerward.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se
+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient’s life and to require minimal rehabilitation. The Company’s focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble’s vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company’s Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se